dwfbrooks
8K posts














Thanks for Fighting with me Against the Evil Trying to Slow down Cures to Disease As I write this, I get tears in my eyes because your support of the efforts at Cure Guardian makes me emotional. I feel like I have poured all I have into fighting against those trying to stop a cure to Alzheimer's. Primarily I have fought this fight as a keyboard warrior The support from you is what keeps me going... A husband that has a wife in the open label trial on $sava simufilam emailed me after the latest @adamfeuerstein tabloid article. He said "I couldn’t resist contacting you after seeing Feuerstein’s once again call for the trials to be halted given his “concern” for Alzheimer’s patients. It speaks volumes that he is still pleading for the trials to be shut down just weeks/month before a read out of the topline results from one of the phase 3s. Of course, if he were sure the drug didn’t work, he wouldn’t need to call for the clinicals to be halted, he would be proven correct very shortly." This man fought with me to persuade Cassava to take the massive business risk to fund ~1900 to continue on a very expensive open label trial. She has stabilized her disease symptoms after likely being on placebo in REFOCUS. He is fighting a 3 front war... He fights for his wife's life against the disease. He is fighting to keep access to a drug that has slowed down his wife's disease. Now he has to fight the evil in the world spreading doubt about the drug for profit. The evil he fights is why I started Cure Guardian. The short selling hedge funds and funders of the efforts to slow drug development are running loose now with no accountability. These sick people use investigative bodies (FBI, SEC, NIH, journals, ORI, and FDA) that we all fund to investigate and choke resources at our innovative and resource strapped biotech's. These investigations massively scale their effort. ORI only finds research misconduct in 3.5% of the allegations waged against research funding at NIH. The media also scales their effort for free and makes advertising and subscription revenue from the accusations. Once the accusations are public... the goal is met and the damage is done. The world has been on a 118 year journey fighting against #AlzheimersDisease since 1906 when it was discovered by Dr. Alois Alzheimer. The disease is challenging enough, but why does our world make Dr. Lindsay Burns and Dr. Hoau-Yan Wang to also have to fight against the trolls in the media, fraud hunting community, and short sellers? Anyway... thank you thank you thank you for your support. For those that want to join the effort, the best way to do that now is to donate. paypal.com/donate/?hosted… To learn more about the 501c3 non profit visit: cureguardian.org @teddyrosenbluth DM me if you want to learn more about the patients that Roger Nicoll and George Perry are not protecting as they claim. I could also explain the EXTREME conflict of interests they have and likely did not disclose to you.






RETHINK phase 3 reads out by Cassava Sciences, $sava, end of November or December of 2024. We know the drug is safe, so it comes down to effectiveness that could be demonstrated in the RETHINK readout. Answering a question on a tweet on what I think the stock price will do this year... Here are my price estimates depending on data: 1. RETHINK does not show stat sig improvement in mild or moderate - Price will likely goto $10 or lower and wait for REFOCUS, but not good and shorts win. 5% chance this happens 2. RETHINK shows stat sig for Mild and not for moderate and not for total. Lets say Mild slows decline by 30% or similar to $lly and $Biib MAB treatments. Stock will goto $50+ after readout then drift up toward a $10B market cap or $250. 5% chance this happens 3. RETHINK beats the MABS and slows mild patients cognition 50% better than placebo. Moderate not significant and total not significant. The stock should goto $80+ then drift to $350 because it will be a blockbuster. 5% chance this happens. 4. RETHINK reads out MILD as improvement in cognition, so a 100% or greater than placebo. Moderate not significant, but overall is significant. Stock should goto $200 instantly, then drift up to $500+. Proves that if you take simufilam early you will not get AD symptoms. 20% chance this happens 5. RESULT I EXPECT - RETHINK reads out as Mild improvement AND Moderate better than placebo. So Mild's improve over 100% to placebo and moderate improve 30-50% decline than placebo. Stock will instantly goto $300 plus and drift toward $2000. Mega blockbuster drug, but slower uptake. 40% chance this happens 6. RETHINK on average improves the entire treatment group cognition at 1 year, so improvement over placebo > 100%. Stock will instantly goto 500 and rise toward $3000+. Mega blockbuster drug that solves the AD crisis and world wide medical and government will get behind getting the drug out as fast as possible. 35% chance this happens.
